Sherry Shen, MD
@sherryshenmd.bsky.social
Breast med onc & researcher at MSKCC, Co-Director of the MSK Lobular Breast Cancer Program, Columbia Med & UMich alum
Reposted by Sherry Shen, MD
Clinical Controversies: Management of the Axilla—
Giacomo Montagna, Lori Pierce, and Sherry Shen will address this topic in a special session at #SABCS25 (December 9-12). Learn more:
buff.ly/ykgbF15
@sherryshenmd.bsky.social
Giacomo Montagna, Lori Pierce, and Sherry Shen will address this topic in a special session at #SABCS25 (December 9-12). Learn more:
buff.ly/ykgbF15
@sherryshenmd.bsky.social
September 9, 2025 at 6:16 PM
Clinical Controversies: Management of the Axilla—
Giacomo Montagna, Lori Pierce, and Sherry Shen will address this topic in a special session at #SABCS25 (December 9-12). Learn more:
buff.ly/ykgbF15
@sherryshenmd.bsky.social
Giacomo Montagna, Lori Pierce, and Sherry Shen will address this topic in a special session at #SABCS25 (December 9-12). Learn more:
buff.ly/ykgbF15
@sherryshenmd.bsky.social
Reposted by Sherry Shen, MD
A big thank you to Dr. Mouabbi @jamouabbi.bsky.social
and Dr. Shen @sherryshenmd.bsky.social for your time and wonderful presentations on lobular cancer. Thank you
@graspcancer.bsky.social for organizing these sessions!
and Dr. Shen @sherryshenmd.bsky.social for your time and wonderful presentations on lobular cancer. Thank you
@graspcancer.bsky.social for organizing these sessions!
June 11, 2025 at 3:36 PM
A big thank you to Dr. Mouabbi @jamouabbi.bsky.social
and Dr. Shen @sherryshenmd.bsky.social for your time and wonderful presentations on lobular cancer. Thank you
@graspcancer.bsky.social for organizing these sessions!
and Dr. Shen @sherryshenmd.bsky.social for your time and wonderful presentations on lobular cancer. Thank you
@graspcancer.bsky.social for organizing these sessions!
Thank you @theaacr.bsky.social for inviting me to speak on integrating GLP-1RAs into clinical cancer care. Great session alongside Drs. Stephen Hursting & Rong Xu. Some data on use in cancer patients now, but so much more needed!
Informative educational session by MSK breast medical oncologist @sherryshenmd.bsky.social, who shared best practices for introducing GLP1-RAs, like #Ozempic, into clinical cancer care. @theaacr.bsky.social
April 27, 2025 at 10:25 AM
Thank you @theaacr.bsky.social for inviting me to speak on integrating GLP-1RAs into clinical cancer care. Great session alongside Drs. Stephen Hursting & Rong Xu. Some data on use in cancer patients now, but so much more needed!
Reposted by Sherry Shen, MD
At #AACR25, join breast medical oncologist @sherryshenmd.bsky.social for an education session on best practices to introduce GLP1-RAs, like Ozempic, into clinical #cancer care. @mskcancercenter.bsky.social @theaacr.bsky.social Learn more: bit.ly/4jso7Ed
3:01-3:21 p.m. CT
3:01-3:21 p.m. CT
April 26, 2025 at 6:30 PM
At #AACR25, join breast medical oncologist @sherryshenmd.bsky.social for an education session on best practices to introduce GLP1-RAs, like Ozempic, into clinical #cancer care. @mskcancercenter.bsky.social @theaacr.bsky.social Learn more: bit.ly/4jso7Ed
3:01-3:21 p.m. CT
3:01-3:21 p.m. CT
Reposted by Sherry Shen, MD
Wrapping up another fantastic #SABCS!
Amazing, practice-changing data were presented.
I’ve updated the algorithms and added key studies from the meeting— I finally ran out of space in HR+ disease!
#SABCS24 @oncoalert.bsky.social
Amazing, practice-changing data were presented.
I’ve updated the algorithms and added key studies from the meeting— I finally ran out of space in HR+ disease!
#SABCS24 @oncoalert.bsky.social
December 13, 2024 at 8:08 PM
Wrapping up another fantastic #SABCS!
Amazing, practice-changing data were presented.
I’ve updated the algorithms and added key studies from the meeting— I finally ran out of space in HR+ disease!
#SABCS24 @oncoalert.bsky.social
Amazing, practice-changing data were presented.
I’ve updated the algorithms and added key studies from the meeting— I finally ran out of space in HR+ disease!
#SABCS24 @oncoalert.bsky.social
When @breastcancerdoc.bsky.social & I are unintentionally matching at our poster on T-DXd in pts with HER2-low lobular MBC. PFS 7.2m in total cohort, shorter in those with PIK3CA/AKT/PTEN muts & trend toward longer in HER2mut. More research needed in lobular BC!
December 13, 2024 at 2:09 PM
When @breastcancerdoc.bsky.social & I are unintentionally matching at our poster on T-DXd in pts with HER2-low lobular MBC. PFS 7.2m in total cohort, shorter in those with PIK3CA/AKT/PTEN muts & trend toward longer in HER2mut. More research needed in lobular BC!
First Bluesky post! EMBER-3 presented by my mentor @breastcancerdoc.bsky.social demonstrating greater mPFS as single agent vs. SOC ET in ESR1mut, and impressive benefit of imlunestrant+abema with mPFS 9.4 months, 59% had prior CDK4/6i. Novel ET + CDK4/6i switch is intriguing - ELAINE3 is enrolling!
December 11, 2024 at 4:21 PM
First Bluesky post! EMBER-3 presented by my mentor @breastcancerdoc.bsky.social demonstrating greater mPFS as single agent vs. SOC ET in ESR1mut, and impressive benefit of imlunestrant+abema with mPFS 9.4 months, 59% had prior CDK4/6i. Novel ET + CDK4/6i switch is intriguing - ELAINE3 is enrolling!